Aldeyra Therapeutics, Inc. ALDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-19.51
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$33.8M | — | — | $44.3M |
| 2024 | — | -$55.9M | — | — | $71.0M |
| 2023 | — | -$37.5M | — | -$30.3M | $119.8M |
| 2022 | — | -$62.0M | — | -$56.7M | $151.0M |
| 2021 | — | -$57.8M | — | -$42.6M | $205.7M |
| 2020 | — | -$37.6M | — | — | $59.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Brady Todd C | President and CEO | 2026-06-03 | Buy | 250,000 | $1.67 |
| DOUGLAS RICHARD | director | 2026-03-19 | Buy | 70,000 | $1.40 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -19.51 (distress)
- Working capital / assets 0.61
- Retained earnings / assets -6.716
- EBIT / assets -0.489
- Equity / liabilities 1.591
Source: SEC EDGAR filings · CIK 0001341235 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.